Purple Patch: US Approval For Cipla's Gx Albuterol, Staggered Supplies Planned

Cipla gets US FDA go-ahead earlier than anticipated for first generic of Merck’s Proventil, setting the stage for increased competition in the albuterol segment, where demand is up amid the coronavirus pandemic.

Cipla Gets US Go-Ahead For Key Respiratory Asset • Source: Shutterstock

Cipla Ltd. appears to have hit a purple patch in terms of forward momentum for its key respiratory assets in the US. After a milestone completion of Phase III studies for its rival version of GlaxoSmithKline PLC's Advair Diskus, the Indian firm has now received the go-ahead for the first generic of Merck Sharp & Dohme Ltd.’s Proventil HFA (albuterol sulfate) metered dose inhaler.

[Sidebar#GB149776]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip